Please consult your physician before taking any medication. Indications: The rifampicina, isoniazida and the pirazinamida one are antitubercular bactericidal drugs. The combination of rifampicina with isoniazida, RIFINAH, is particularly active against extracellular microorganisms of fast growth and presents/displays an intracellular bactericidal activity. The isoniazida one acts against bacilli of the tuberculosis in active growth. The contained pirazinamida one in RIFATER is active against intracellular microorganisms, mainly in acid means of the macrophages. The rifampicina is active against M. tuberculosis of slow and intermittent growth. Therefore, the three agents rifampicina, isoniazida and pirazinamida present/display activity against different states and activities from the M. tuberculosis. In sensible cells, the rifampicina inhibits the activity of the RNA dependent polymerase of Mrs Specifically interacts with the bacterial RNA polymerase, and it does not inhibit to the enzyme of mammals. The crossed resistance to rifampicina has been only demonstrated with other rifamicinas. Pharmacokinetics: Studies of pharmacokinetics in healthy volunteers demonstrated that the three and two components of RITATER and RIFINAH, respectively, have a comparable bioavailability if they are administered together in the form of personal doses or like RIFATER or RIFINAH. Rifinah may also be used for purposes other than those listed in this medication guide.